









Markets
/
Stocks
/
nasdaq-fbio
/

Fortress Biotech Inc

FBIO

3.270USD

+0.340+11.60%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

101.39MMarket Cap

LossP/E TTM



Fortress Biotech Inc

3.270

+0.340+11.60%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Fortress Biotech Inc

Currency: USD Updated: 2026-02-06

Key Insights

Fortress Biotech Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 86 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.75.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fortress Biotech Inc's Score

Industry at a Glance

Industry Ranking

86 / 159

Overall Ranking

231 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Fortress Biotech Inc Highlights

StrengthsRisks

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Growing

The company is in a growing phase, with the latest annual income totaling USD 57.67M.

Undervalued

The company’s latest PE is -32.26, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 1.10M shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.750

Target Price

+266.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Fortress Biotech Inc is 7.45, ranking 114 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.63M, representing a year-over-year increase of 20.52%, while its net profit experienced a year-over-year increase of 124.43%.

Score

Industry at a Glance

Previous score

7.45

Change



Financials

6.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.77

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Fortress Biotech Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Fortress Biotech Inc is 7.96, ranking 37 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -32.26, which is -100.07% below the recent high of 0.02 and -33.94% above the recent low of -43.21.

Score

Industry at a Glance

Previous score

7.96

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 86/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Fortress Biotech Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 10.75, with a high of 17.00 and a low of 4.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.750

Target Price

+266.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Fortress Biotech Inc

FBIO

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Fortress Biotech Inc is 6.48, ranking 125 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.23 and the support level at 2.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.12

Change

0.36

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.115

Sell

RSI(14)

46.702

Neutral

STOCH(KDJ)(9,3,3)

34.417

Buy

ATR(14)

0.208

Low Volatility

CCI(14)

-50.574

Neutral

Williams %R

51.351

Neutral

TRIX(12,20)

-0.644

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.104

Buy

MA10

3.222

Buy

MA20

3.446

Sell

MA50

3.380

Sell

MA100

3.131

Buy

MA200

2.595

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Fortress Biotech Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 26.50%, representing a quarter-over-quarter decrease of 3.02%. The largest institutional shareholder is The Vanguard, holding a total of 1.10M shares, representing 3.55% of shares outstanding, with 39.26% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Rosenwald (Lindsay A)

4.11M

-27.60%

Weiss (Michael S)

1.80M

The Vanguard Group, Inc.

Star Investors

950.33K

+11.42%

Summit Financial, LLC

444.75K

-56.22%

Susquehanna International Group, LLP

356.18K

+680.49%

Shikiar Asset Management, Inc.

278.47K

Geode Capital Management, L.L.C.

244.42K

+4.10%

Northern Trust Investments, Inc.

220.64K

+136.67%

Sculptor Capital Management, Inc

208.90K

Kestra Advisory Services, LLC

196.88K

-40.70%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fortress Biotech Inc is 3.60, ranking 102 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.42. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.